1. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial 
Shun Ishibashi, MD, PhD, Hidenori Arai, MD, PhD, Koutaro Yokote, MD, PhD, Eiichi Araki, MD, PhD, Hideki Suganami, PhD, Shizuya Yamashita, MD, PhD 
Journal of Clinical Lipidology 
Volume 12, Issue 1, Pages (January 2018)
DOI: /j.jacl
Copyright © 2017 National Lipid Association Terms and Conditions

2. Figure 1
Change from baseline over time in liver enzymes. Data are presented as mean changes from baseline in liver enzymes in the pemafibrate 0.2 mg/d (⧫), pemafibrate 0.4 mg/d (■), and fenofibrate 106.6 mg/d (▲) groups. (A) Alanine aminotransferase (ALT); (B) aspartate aminotransferase (AST); (C) gamma-glutamyltransferase (γ-GT); (D) alkaline phosphatase (ALP). Parentheses indicate the number of patients. Error bars indicate standard deviation. ∗∗∗P < .001, ∗∗P < .01, ∗P < .05 vs baseline tested by 1-sample t-test. †††P < .001, ††P < .01, †P < .05 vs fenofibrate tested by analysis of covariance.
Journal of Clinical Lipidology  , DOI: ( /j.jacl )
Copyright © 2017 National Lipid Association Terms and Conditions

3. Figure 2
Change from baseline over time in parameters of kidney function. Data are presented as mean changes from baseline in parameters of kidney function in the pemafibrate 0.2 mg/d (⧫), pemafibrate 0.4 mg/d (■), and fenofibrate 106.6 mg/d (▲) group. (A) Estimated glomerular filtration rate (eGFR); (B) serum creatinine (SCr); (C) cystatin C. Parentheses indicate the number of patients. Error bars indicate standard deviation. ∗∗∗P < .001, ∗∗P < .01, ∗P < .05 vs baseline tested by 1-sample t-test. †††P < .001, ††P < .01, †P < .05 vs fenofibrate tested by analysis of covariance.
Journal of Clinical Lipidology  , DOI: ( /j.jacl )
Copyright © 2017 National Lipid Association Terms and Conditions